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nflammation, as Measured by the
rythrocyte Sedimentation Rate,
s an Independent Predictor
or the Development of Heart Failure
rik Ingelsson, MD,* Johan A¨rnlöv, MD, PHD,* Johan Sundström, MD, PHD,* Lars Lind, MD, PHD†‡
ppsala and Mölndal, Sweden
OBJECTIVES Our objective was to explore inflammation, measured as erythrocyte sedimentation rate
(ESR), as a predictor for the development of heart failure (HF).
BACKGROUND In recent years, evidence of the importance of inflammation in the pathophysiology of HF has
emerged, and various inflammatory markers have been found to predict future HF.
Erythrocyte sedimentation rate is an inexpensive and easily accessible marker of systemic
inflammation, but to this date it is unknown whether ESR predicts subsequent HF.
METHODS In a community-based prospective study of 2,314 middle-aged men free from HF, myocardial
infarction, and valvular disease at baseline, ESR was analyzed in multivariable models
together with established risk factors for HF (hypertension, diabetes, electrocardiographic left
ventricular hypertrophy, smoking, obesity, and serum cholesterol) and hematocrit.
RESULTS A total of 282 men developed HF during a median follow-up time of 30 years. In Cox
proportional hazards analyses, ESR was an independent predictor of HF (hazard ratio 1.46
for highest quartile vs. the lowest, 95% confidence interval 1.04 to 2.06). This observation
remained significant when also adjusting for interim myocardial infarction during follow-up.
CONCLUSIONS Erythrocyte sedimentation rate was a significant predictor of HF, independent of established
risk factors for HF, and interim myocardial infarction after three decades of follow-up in a
population-based sample of middle-aged men. Our findings indicate that inflammation
occurs early in the process leading to HF and that ESR could be used to evaluate this
process. (J Am Coll Cardiol 2005;45:1802–6) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.066Cardiology Foundation
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tn recent years, the association between inflammation and
ardiovascular diseases has gained considerable interest (1).
everal systemic markers of inflammation, including eryth-
ocyte sedimentation rate (ESR), have been found to be
redictors of coronary heart disease (2–4). C-reactive pro-
ein, tumor necrosis factor (TNF)-alpha, and interleukin
IL)-6, all markers of cytokine-mediated inflammation,
ave all been shown to predict incident heart failure (HF)
5,6), but to this date, there are no studies of the possible
ssociation between ESR and future HF. The ESR is a
ell-validated and inexpensive tool for evaluating inflam-
ation (including aspects of inflammation other than
ytokine-mediated reactions) and is available at every out-
atient clinic.
Thus, our aim was to analyze ESR as a possible predictor
f heart failure during a median follow-up time of 30 years
n a community-based sample of middle-aged men free
rom HF, previous acute myocardial infarction, and valvular
isease at baseline. Because ESR is a known predictor of
From the Departments of *Public Health and Caring Sciences and †Medical
ciences, Uppsala University, Uppsala, Sweden; and ‡Astra Zeneca R & D, Mölndal,
weden. Sources of support: Primary Health Care in Uppsala County, Swedish Heart
ung Foundation (Hjärt-Lungfonden), and Thuréus Foundation. The funding
ource had no involvement in the work reported in this paper.i
Manuscript received December 14, 2004; revised manuscript received February 16,
005, accepted February 22, 2005.oronary heart disease, a secondary aim was to analyze
hether it predicted HF independently of an interim
yocardial infarction during the follow-up period.
ETHODS
tudy sample. The study used the Uppsala Longitudinal
tudy of Adult Men (ULSAM) cohort, to which all
0-year-old men living in Uppsala county in 1970 to 1974
ere invited. Of the 2,841 invited men, 82% (2,322 men)
articipated in the investigation (7). The ULSAM study is
escribed in detail on the Internet (8). None of the subjects
ad been diagnosed with HF in the hospital discharge
egister before baseline. Seven subjects were excluded be-
ause of previous myocardial infarction and one subject
ecause of valvular disease at baseline; thus, 2,314 men were
ligible for the investigation. In a secondary analysis, we
xcluded all subjects receiving treatment with corticoste-
oids (n  7) or potentially anti-inflammatory analgesics
n  16). All subjects gave written consent, and the
thics Committee of Uppsala University approved the
tudy.
xaminations at baseline. Examinations performed when
he subjects were 50 years of age (7) included a structured
nterview; a questionnaire; blood sampling (after an over-
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June 7, 2005:1802–6 ESR and HFight fast) for glucose, lipid, and ESR determinations; an
lectrocardiogram; and a physical examination with deter-
inations of supine blood pressure and anthropometric
easurements.
The ESR was determined by Westergren’s method. Body
ass index (BMI) was calculated as weight (in kg) divided
y height (in m) squared (kg/m2). The presence of hyper-
ension at baseline was defined as systolic blood pressure
140 mm Hg or diastolic blood pressure 90 mm Hg,
nd/or the use of antihypertensive medication. The presence
f diabetes at baseline was defined as fasting blood glucose
6.1 mmol/l and/or the use of oral hypoglycemic agents or
nsulin. Electrocardiographic left ventricular hypertrophy
as defined as high amplitude R-waves according to the
evised Minnesota code (9) together with a left ventricular
train pattern (10). The presence of valvular disease (Inter-
ational Classification of Diseases [ICD]-8 codes 394-396
nd 424, ICD-9 codes 394-397 and 424, or ICD-10 codes
05-I08 and I34-I37) and previous myocardial infarction
ICD-8 code 410, ICD-9 code 410, or ICD-10 code I21)
ere assessed from the hospital discharge register.
ollow-up and outcome parameter. The subjects had a
edian follow-up time of 29.6 years (range, 0.04 to 32.7
ears), contributing to 59,122 person-years at risk. The
ossible HF cases were selected by linking the ULSAM
articipants to the hospital discharge register using the
wedish unique personal identification numbers. As a pos-
ible diagnosis of heart failure, we considered ICD heart
ailure codes 427.00, 427.10, 428.99 (ICD-8), 428 (ICD-
), and I50 (ICD-10) and hypertensive heart disease with
eart failure, I11.0 (ICD-10), which were allowed in any of
he six possible diagnosis positions. Three hundred forty-six
en had a hospital discharge register diagnosis of HF
etween the entry to the ULSAM study and the end of
002. The medical records from the relevant hospitalization
ere reviewed by two physicians (E.I. and L.L.), blinded to
he baseline data, who classified the cases as definite,
uestionable, or miscoded. The classification relied on the
efinition proposed by the European Society of Cardiology
11). After this validation, 282 cases of definite HF were
ncluded in the present study. None of the subjects was lost
o follow-up.
tatistical methods. Data are given as means  SD and
Abbreviations and Acronyms
BMI  body mass index
CI  confidence interval
ESR  erythrocyte sedimentation rate
HF  heart failure
HR  hazard ratio
ICD  International Classification of Diseases
IL  interleukin
TNF  tumor necrosis factor
ULSAM  Uppsala Longitudinal Study of Adult Menercent. Proportional hazards assumptions were confirmed (oth graphically and by Schoenfeld’s tests. Cumulative
azard curves according to ESR levels were established by
he Nelson-Aalen estimation method (12). Inspecting HF
ncidence rates in quartiles of ESR, an apparent threshold
evel at the median was observed (Fig. 1). On the basis of
his, we assessed ESR as a nominal variable, both as four
roups (quartiles) and as two groups (above vs. below or at
he median). In the quartiles models, the lowest HF
ncidence was observed in the second quartile of ESR (Fig.
), which was used as a reference level. The prognostic value
f ESR for HF incidence was investigated using Cox
roportional hazards analyses. We investigated three sets of
odels in a hierarchical fashion: 1) unadjusted analyses; 2)
ultivariable-adjusted analyses using the following baseline
ovariates: hypertension, diabetes, electrocardiographic left
entricular hypertrophy, smoking, BMI, serum cholesterol,
nd hematocrit; and 3) covariates as in model 2, with the
ddition of interim myocardial infarction during follow-up.
Hematocrit was included as a covariate in models 2 and 3,
ogether with the established risk factors for HF, to adjust
or the red blood cell characteristics, leaving ESR to reflect
ainly systemic inflammation. Two-tailed 95% confidence
ntervals (CIs) and p values are given, with p  0.05
egarded as significant. All analyses were specified a priori.
tatistical software package STATA 8.2 (Stata Corp.,
ollege Station, Texas) was used.
ESULTS
he incidence rate for HF during the follow-up period was
.8/1,000 person-years at risk. Table 1 shows the participant
haracteristics at baseline. In unadjusted Cox proportional
azards analyses, ESR was significantly associated with HF
ncidence, with the highest hazard ratio observed in the
ighest quartile of ESR compared with the reference level
igure 1. Incidence rates of congestive heart failure (CHF) by quartiles
quartile 1, erythrocyte sedimentation rate [ESR]  1 to 3 mm/h; quartile
, 4 to 6 mm/h; quartile 3, 7 to 10 mm/h; quartile 4, 11 to 83 mm/h) of
SR. Lines indicate 95% confidence intervals.Fig. 1, Table 2 middle column). In addition, an ESR
g
c
(
f
e
g
p
p
v
s
i
t
H
t
h
b
h
w
1
m
r
p
t
w
1
f
a
s
D
I
f
d
T
P
P
E
C
B
S
H
E
V
T
F
R
E
V
C
t
(
f
s
F
c
b
[
1804 Ingelsson et al. JACC Vol. 45, No. 11, 2005
ESR and HF June 7, 2005:1802–6reater than the median was a predictor of future HF
ompared with an ESR less than or equal to the median
Table 2, middle column). A cumulative HF incidence plot
or ESR split by the median is presented in Figure 2. When
valuating ESR as a diagnostic test for future HF (ESR
reater than the median [6 mm/h] considered to be a
ositive test), the sensitivity was 48%, specificity 57%,
ositive predictive value 13%, and the negative predictive
alue was 89%. As a comparison, we calculated the corre-
ponding values for hypertension (sensitivity 57%, specific-
ty 59%, positive predictive value 16%, and negative predic-
ive value 91%). Adjusting for established risk factors for
F (hypertension, diabetes, electrocardiographic left ven-
ricular hypertrophy, smoking, BMI, serum cholesterol) and
ematocrit, ESR remained a significant predictor of HF in
oth the dichotomous and the quartile Cox proportional
azards models (Table 2, right column).
Evidence of myocardial infarction during the follow-up
as present in 411 of the subjects in the total cohort and in
able 1. Baseline Characteristics of the Cohort
revalence of hypertension (%) 43
revalence of diabetes (%) 5.6
lectrocardiographic left
ventricular hypertrophy (%)
1.7
urrent cigarette smoking (%) 51
ody mass index (kg/m2) 25.0  3.2
-cholesterol (mmol/l) 6.9  1.3
ematocrit (%) 43.4  2.7
rythrocyte sedimentation rate
(mm/h)
7.8  7.0 (median 6, range 1–83)
alues are means  SD or %.
able 2. Incidence of Heart Failure in Relation to Erythrocyte Se
ree From Heart Failure (HF), Myocardial Infarction, and Valvu
isk Factors
f
stablished risk factors for HF
Prevalence of hypertension 2
Prevalence of diabetes 1
Electrocardiographic left ventricular hypertrophy 5
Current cigarette smoking 1
Body mass index (kg/m2) 1
S-cholesterol (mmol/l) 1
ariables of ESR
Quartiles of ESR
First quartile (ESR  1–3 mm/h) 1
Second quartile (ESR  4–6 mm/h)
Third quartile (ESR  7–10 mm/h) 1
Fourth quartile (ESR  11–83 mm/h) 1
Split by the median of ESR
Below or at the median (ESR  1–6 mm/h)
Above median (ESR  7–83 mm/h) 1
ox proportional hazards ratios for a 1-standard deviation increase in continuous vari
he level with the lowest incidence rate was used as the reference level. Data are hazar
hypertension, diabetes, electrocardiographic left ventricular hypertrophy, smoking, bo
actors in the right column are acquired from the multivariable model incorporating erythroc
ignificant. *p  0.05; †p  0.01; ‡p  0.001.07 of the 282 HF cases (38%). When adjusting for interim
yocardial infarction in addition to the established baseline
isk factors for HF, an ESR in the highest quartile (com-
ared with quartile 2; hazard ratio [HR] 1.46, 95% CI 1.04
o 2.05, p  0.03) and greater than the median (compared
ith less than or equal to the median; HR 1.35, 95% CI
.06 to 1.72, p  0.01) remained significant predictors of
uture HF. In the subsample free from corticosteroids and
nti-inflammatory analgesics, the results were essentially the
ame in all models (data not shown).
ISCUSSION
n this community-based cohort study of middle-aged men
ree from heart failure, myocardial infarction and valvular
isease at baseline, erythrocyte sedimentation was a signif-
entation Rate (ESR) in the Total Sample (n  2,314)
isease at Baseline, Unadjusted and Adjusted for Established
djusted
ard ratio
(95% CI)
Adjusted for Established Risk Factors
and Hematocrit
Hazard Ratio for HF
(95% CI)
.69–2.71)‡ 1.66 (1.29–2.13)‡
.16–2.72)† 1.58 (1.03–2.44)*
.16–9.30)‡ 4.52 (2.60–7.83)‡
.19–1.91)‡ 1.70 (1.33–2.17)‡
.44–1.77)‡ 1.48 (1.33–1.65)‡
.06–1.32)† 1.09 (0.97–1.23)
.79–1.51) 1.14 (0.82–1.60)
1 1
.93–1.77) 1.34 (0.97–1.86)
.06–2.08)* 1.46 (1.04–2.06)*
1 1
.04–1.66)* 1.31 (1.03–1.67)*
r transfer from one level to another of categorical variables. For categorical variables,
s (95% confidence intervals [CI]), unadjusted or adjusted for established risk factors
ss index and serum cholesterol) and hematocrit. The values shown for established risk
igure 2. Nelson-Aalen plot of cumulative incidence of heart failure in the
ohort free from heart failure, myocardial infarction, and valvular disease at
aseline by two groups (greater than vs. less than or equal to the median
erythrocyte sedimentation rate (ESR) 6 mm/h]) of ESR.dim
lar D
Una
Haz
or HF
.14 (1
.77 (1
.42 (3
.51 (1
.59 (1
.18 (1
.09 (0
.28 (0
.49 (1
.31 (1
ables o
d ratio
dy mayte sedimentation rate (ESR) split by the median. Any p values 0.05 are considered
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June 7, 2005:1802–6 ESR and HFcant predictor of HF, taking established risk factors for HF
nd hematocrit at baseline and interim myocardial infarc-
ion during follow-up into account. Our observations indi-
ate that inflammation might be an important factor that
ccurs early in the process leading to HF. This fact is further
upported by the lag time of one decade before development
f HF observed in this cohort (Fig. 2). The diagnostic
apacity of ESR as a test for incident HF, in terms of
ensitivity and specificity, was comparable with that of
ypertension.
revious studies. In the last decade, evidence of inflam-
ation as a crucial part of the atherosclerosis process has
merged (1). Inflammation can be initiated in the vessels as
response to retained and modified low-density-lipoprotein
holesterol, injury, and infections. Other major risk factors
or cardiovascular diseases, such as hypertension, diabetes,
besity, and smoking, also have been associated with a
ow-grade chronic inflammation (1,13). In recent years, the
ole of inflammation in the pathogenesis of HF has been
nvestigated. Elevated levels of various inflammatory mark-
rs have been observed in patients with HF (14,15) and, in
ecent prospective studies, increased levels of C-reactive
rotein, TNF-alpha, and IL-6, markers of cytokine-
ediated inflammation, predicted subsequent HF (5,6).
esari et al. (5) used a study sample about as large as ours,
hereas Vasan et al. (6) used a smaller sample with slightly
ore than 700 subjects. Both studies had much shorter
ollow-up (3.6 years and 5.2 years, respectively), and fewer
F cases (92 and 56 cases, respectively) than our study. The
ubjects in these studies were older (mean age, 74 and 78
ears, respectively). The hazard ratios observed for high
ersus low levels of the studied cytokines in these studies
ere somewhat higher than for high versus low ESR in our
tudy, but it is difficult to draw any firm conclusions about
ossible differences in the strengths of associations between
he various inflammatory markers and HF because of the
arge differences in study design.
C-reactive protein, TNF-alpha, and IL-6 are specific
arkers of cytokine-mediated inflammation but provide no
nformation about other (potentially equally or more impor-
ant) aspects of inflammation. The ESR is a less-specific
arker of systemic inflammation that is known to be
levated in many acute and chronic diseases characterized by
issue necrosis and inflammation. It is a simple and inex-
ensive laboratory test that is in widespread use and is easily
ccessible. In his classic report, Wood observed a low ESR
n a small sample of patients with HF of different origins
16), but more recent studies have reported that in patients
ith manifest HF a high ESR is associated with a more
evere stage of HF and a worse prognosis (14,15). The
forementioned studies have examined the association be-
ween ESR and already diagnosed HF (14–16), whereas the
resent study is the first to examine ESR as a predictor of
ubsequent incident HF.ossible mechanisms. The ESR has repeatedly been
ound to be a predictor of subsequent coronary heart
isease in longitudinal studies (2–4). Nonetheless, in the
resent study the association between ESR and HF
emained significant, even after adjusting for interim
yocardial infarction, which may indicate that inflam-
ation could directly impair myocardial function. Previ-
us studies have shown that proinflammatory cytokines,
uch as TNF-alpha, can depress myocardial contractility
17) and affect left ventricular remodeling through local
nduction of matrix metalloproteinases (18,19). Inflam-
ation also can induce endothelial dysfunction in small
essels (20), resulting in an impaired coronary flow
eserve and impaired left ventricular function.
trengths and limitations. The strengths of this study
nclude the large population, the long follow-up period, and
he detailed characterization of the cohort. Furthermore, all
F cases were validated, limiting the inclusion of false-
ositive cases. Some limitations to this study exist. Because
e only examined men of the same age with a similar ethnic
ackground, this study has an unknown generalizability to
omen and other age and ethnic groups. Furthermore,
ecause this study was initiated in the 1970s and the HF
iagnosis was based on a review of medical records, it was
ot possible to differentiate between systolic and diastolic
eart failure as echocardiography was not available at the
ime of diagnosis for many of the cases. At that time, ESR
as the only measured inflammatory marker; thus, it was
ot possible to directly compare ESR and other inflamma-
ory markers as predictors of HF in this study.
onclusions. Inflammation measured as ESR was a sig-
ificant predictor of HF, independent of established risk
actors for HF, including an interim myocardial infarction,
fter almost three decades of follow-up in a population-
ased sample of middle-aged men. Further research is
arranted to determine potential gender and ethnic varia-
ions of the relation between inflammation and HF inci-
ence and to compare ESR with other markers of inflam-
ation as predictors of incident congestive heart failure.
eprint requests and correspondence: Dr. Erik Ingelsson, De-
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eriatrics, Uppsala University, Box 609, SE-75125 Uppsala,
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